Related Experiment Video
Updated: May 16, 2026
Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer
Published on: May 20, 2016
Non-invasive prediction of prognostic immune subtypes in lung adenocarcinoma using PET/CT-based radiomics
Sijia Zhang1, Yang Wang2, Dong Dai1
1Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Background:
The treatment and prognosis of lung adenocarcinoma (LUAD) remain major clinical challenges. While transcriptomic profiling can define immune subtypes, its invasive nature limits clinical utility.
Objectives:
We aimed to bridge this translational gap by developing and validating a non-invasive 18F-FDG PET/CT radiomics-based biomarker to predict these subtypes and assess their therapeutic relevance.
Methods:
We performed consensus clustering on transcriptomic data from 773 LUAD patients (TCGA/GEO) to identify novel immune subtypes, developed a radiomics-based machine learning classifier using their PET/CT data (n=115) and conducted a biologically and clinically supported external evaluation in an independent cohort from Tianjin Medical University Cancer Hospital (TMUCIH, n=249). In this cohort, we compared immune patterns with transcriptomic subtypes via immunohistochemical staining, and their prognostic significance was evaluated in patients receiving EGFR tyrosine kinase inhibitors (n=118) and immune checkpoint inhibitors (n=75).
Results:
We identified three robust immune subtypes (log-rank p=0.0017): Inflammatory (ClusterA), Activated (ClusterB), and Evasive (ClusterC). Our radiomics model predicted these subtypes with high accuracy (one-vs-rest AUC = 0.84). Immunohistochemical patterns were consistent with predicted subtypes and stratified overall survival in both the TKI-treated (log-rank p-value=0.041) and ICI-treated (log-rank p-value =0.024) cohorts. These results support a validated, non-invasive approach linking genomics and radiomics to enhance patient stratification and guide personalized treatment strategies in LUAD.
